Streetbeat News

XCUR

Exicure, Inc.

https://www.exicuretx.com

Industry

Biotechnology

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Open

8.30

Mkt cap

22M

Volume

9.4K

High

8.55

P/E Ratio

-4.23

52-wk high

36.00

Low

8.00

Div yield

N/A

52-wk low

1.44

Exicure, Inc. has announced a purchase agreement with GPCR Therapeutics, Inc. This development may have implications for Exicure's business operations and stock performance.

Portfolio Pulse from

January 23, 2025 | 5:30 am

Exicure, Inc. has announced a partnership with GPCR Therapeutics Inc. to drive new growth in the biotech sector. This collaboration is expected to enhance Exicure's capabilities and market position.

Portfolio Pulse from

December 27, 2024 | 1:30 am

Exicure, Inc. has announced that its shareholders have approved an $8.7 million equity financing. Additionally, the company reported changes in its executive management and board.

Portfolio Pulse from

December 20, 2024 | 10:00 pm

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

The article highlights significant intraday movements in healthcare stocks, with NewGenIvf Group, Gritstone Bio, and Vicarious Surgical among the top gainers, while Seelos Therapeutics and Mainz Biomed are notable losers.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 4:32 pm

Exicure shares experienced a trading halt due to a circuit breaker triggered by a downside move, but the stock has since rebounded and is now up by 6.59%.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 3:35 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. Notable gainers include Carmell (CTCX), Clearside Biomedical (CLSD), and Kezar Life Sciences (KZR), while Nexalin Technology (NXL) and Tivic Health Systems (TIVC) were among the losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 12:07 pm

In Tuesday's after-market session, several healthcare stocks experienced significant price movements. Kezar Life Sciences (KZR) led the gainers with a 28.2% increase, while Nexalin Technology (NXL) saw the largest decline, dropping 14.7%.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:31 pm

Nike shares surged 7% in pre-market trading following the announcement of Elliott Hill as the new CEO. Other stocks also showed significant pre-market movements, including Banzai International, Battalion Oil, and FedEx, which reported weaker-than-expected results.

Portfolio Pulse from Avi Kapoor

September 20, 2024 | 10:00 am

On September 19th, significant market movements were observed for Galmed Pharmaceuticals, Edgewise Therapeutics, and Exicure. Galmed plans to expand its drug development with two new programs. Edgewise reported top-line data from its trials, and Exicure received a Nasdaq extension.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.